Biocardia Inc., of San Carlos, Calif., completed treatment of patients in the 10-patient roll-in cohort for its pivotal phase III Cardiamp Heart Failure Trial testing Cardiamp cell therapy system, designed to deliver a patient's own bone marrow cells directly to the heart after a heart attack.